Literature DB >> 7975858

Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs.

M Kazanji1, F Laurent, P Péry.   

Abstract

Immunostimulating complexes (ISCOMs) were built after treatment of a purified surface protein from Eimeria falciformis sporozoites with a palmitic acid derivation, leading to a high ratio (33-64%) of P27 incorporation in these cage-like structures. P27 kept its antigenicity after incorporation in ISCOMs, which induced, after iterative intubations by the oral route to groups of mice, a systemic IgG response, a local IgA response, and a local enhanced cellular response as demonstrated by lymphoproliferation of mesenteric lymph node cells upon in vitro stimulation with antigen. This immunization (120 micrograms in six oral doses at 2-day intervals) afforded mice a partial protection (60%) against a subsequent 400 oocyst challenge. The reduction in daily oocyst excretion was corroborated by significantly different weight losses between immunized and control mice on days 9 and 10 postinfection and the subsequent death of these control mice. These observations provide the first application of ISCOMs to parasitic intestinal diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975858     DOI: 10.1016/0264-410x(94)90288-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes.

Authors:  Neil C Robson; Helen Beacock-Sharp; Anne M Donachie; Allan McI Mowat
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

3.  Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.

Authors:  N Debard; D Buzoni-Gatel; D Bout
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Oral vaccination against coccidiosis: responses in strains of mice that differ in susceptibility to infection with Eimeria vermiformis.

Authors:  M E Rose; P Hesketh; D Wakelin
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

5.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

6.  Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses.

Authors:  M Ugozzoli; D T O'Hagan; G S Ott
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

7.  Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin-4 or interferon-gamma.

Authors:  R E Smith; A M Donachie; F H McLaren; A M Mowat
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

8.  Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.

Authors:  Neil C Robson; Helen Beacock-Sharp; Anne M Donachie; Allan McI Mowat
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

Review 9.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

Review 10.  Vaccine delivery using nanoparticles.

Authors:  Anthony E Gregory; Richard Titball; Diane Williamson
Journal:  Front Cell Infect Microbiol       Date:  2013-03-25       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.